Schedule - Future of Oncology Summit 2026

SCHEDULE

Day 1: AI, Data Science, and Innovation in Cancer Management

Monday, November 9, 2026

8:00–8:30 AM

Registration and Breakfast

8:30–8:45 AM

OPENING Welcome and Opening Remarks

David Scheer, President, Scheer & Company

Eric Winer, Director, Yale Cancer Center

Jodie Gillon, President and CEO, BioCT

8:45–8:55 AM

SPECIAL SPEAKER Introductory Remarks

Governor Ned Lamont, State of Connecticut (invited)

8:55–9:25 AM

FIRESIDE CHAT Investing for the Future of Oncology Using Digital Tools and Platforms

Annie Lamont, Co-Founder and Managing Partner, Oak HC/FT Moderator: David Scheer, President, Scheer & Company

9:25–9:45 AM

OPENING KEYNOTE AI and the Practice of Oncology: Can It Bend the Curves for Quality and Cost?

Clifford Hudis, Chief Executive Officer, American Society of Clinical Oncology (ASCO)

9:45–10:15 AM

KEYNOTE The State of Affairs in Breast Cancer

Eric Winer, Director, Yale Cancer Center

10:15–10:45 AM

BREAK

10:45–11:20 AM

PANEL The State of Affairs in Lung Cancer

Sarah Goldberg, Chief of Thoracic Oncology, Co-Director of the Center for Thoracic Cancers, Yale Cancer Center

Katerina Politi, Joseph A. and Lucille K. Madri Professor of Pathology and Internal Medicine, Yale University

Moderator: Vicky Brown, US Head of Oncology and Emerging Disease Areas, Boehringer Ingelheim

11:20–11:40 AM

MINI-KEYNOTE A Journey Back into Oncology Innovation: Case Study of a Large Biopharma’s Reemergence in Oncology R&D

Hesham A. Abdullah, Senior Vice President, Global Head of Oncology R&D, GSK

11:40 AM–12:05 PM

MINI-KEYNOTE The State of Affairs in Brain Cancer: A Next Frontier?

Ranjit Bindra, Kate Cushing Professor of Therapeutic Radiology, Yale School of Medicine; Co-Director, Yale Brain Tumor Center

12:00–12:30 PM

FIRESIDE CHAT AI in Drug Discovery and Development

Mikael Dolsten, Former Chief Scientific Officer and President of R&D, Pfizer

Moderator: David Scheer, President, Scheer & Company

12:30–12:50 PM

FIRESIDE CHAT Oncology Innovation as a Strategic Priority

David Hyman, Chief Medical Officer, Eli Lilly

Moderator: Jeffrey Sonnenfeld, Sr. Associate Dean for Leadership Studies and the Practice of Management, CEO Yale CEO Leadership Institute, Yale School of Management

12:50–1:50 PM

Lunch and Networking: Visit with Boehringer Ingelheim

1:50–2:20 PM

FIRESIDE CHAT Moving Into Earlier Stages Of Disease: What Does Functional Cure Look Like And How Do We Achieve It?

Susan Galbraith, Executive Vice-President, Oncology R&D, AstraZeneca

Moderator: Martin Mackay, Former Head of R&D at Pfizer, AstraZeneca, and Alexion

2:20–2:50 PM

PANEL Rare Pediatric Oncology Innovation and Advocacy

Peter Adamson, Global Head, Oncology Development, Servier Pharmaceuticals

Max Colao, Chief Executive Officer, OncoVerity

Pamela Gavin, Chief Executive Officer, NORD

Ching Lau, Scientific Director, Center for Cancer and Blood Disorders, Connecticut Children’s; Professor, The Jackson Laboratory for Genomic Medicine

Moderator: Mike Apkon, President, Sand Street Advisors, LLC; Former Vice President Yale Children’s Hospital; Former Chief Executive Officer, The Hospital for Sick Children, Toronto, and Tufts Medical Center

2:50–3:25 PM

PANEL Technology Platforms, Precision Medicine and Clinical Translation: Conversation from the C-Suite

Robert Plenge, Executive Vice President, Chief Research Officer, Bristol Myers Squibb

Cristian Massacesi, Executive Vice President, Chief Medical Officer, Head of Development, Bristol Myers Squibb

Moderator: Brian Alexander, Chief Executive Officer, Valo Health, formerly CEO Foundation Medicine

3:25–3:55 PM

BREAK

3:55–4:15 PM

MINI-KEYNOTE The Role of Diagnostics Across the Continuum: From Innovation to Cancer Management

Anne-Renee Hartman, Chief Medical Officer, Adela

4:15–4:35 PM

MINI-KEYNOTE Innovation in AI-Enabled Medical Devices for Cancer Diagnostics and Treatment

Austin Chiang, Chief Medical Officer, Medtronic Global Endoscopy

4:35–5:05 PM

Case Study for a Transformative Deal in Oncology: Halda/JNJ

Yusri Elsayed, Senior Vice President & Global Oncology Therapeutic Area Head, Johnson & Johnson Innovative Medicine

Kat Kayser-Bricker, Chief Scientific Officer, Halda Therapeutics

Tim Shannon, General Partner, Canaan

Moderator: Rachel Humphrey, CEO, Normunity

5:05–5:15 PM

Reflections of Day 1

David Scheer, President, Scheer & Company

Eric Winer, Director, Yale Cancer Center

5:30–7:00 PM

Evening Reception and Networking

Day 2: Therapeutics, Investment, and Strategic Collaboration

Tuesday, November 10, 2026

8:00–8:30 AM

Registration and Breakfast

8:30–8:45 AM

OPENING Welcome and Day 2 Overview

David Scheer, President, Scheer & Company

Eric Winer, Director, Yale Cancer Center

8:45–8:55 AM

OPENING KEYNOTE The State of The State

Daniel O’Keefe, Commissioner, Department of Economic and Community Development Chief Innovation Officer, State of CT

8:55–9:30 AM

PANEL Academic and Industry Collaboration in Oncology Clinical Translation

Ian Krop, Chief Clinical Research Officer, Yale Cancer Center

Patricia LoRusso, Director, Early Phase Clinical Trials Program, Yale Cancer Center

William Oh, Director, Precision Medicine, Yale Cancer Center

Moderator: Jane Healy, Vice President, Therapeutic Area Head, Early Stage Oncology, Global Clinical Development, Merck

9:30–9:50 AM

FIRESIDE CHAT AI Innovation and the Role of Peer-Reviewed Publications

Raja-Elie Abdulnour, Chief Clinical Innovation Officer and Editor of NEJM Clinician, NEJM Group

Harlan Krumholz, Professor of Medicine(Cardiology), Director of Yale Center for Outcomes Research and Evaluation, Editor-in-Chief, Journal of the American College of Cardiology (Invited)

Moderator: Sanjay Aneja, Associate Professor, Therapeutic Radiology (Invited)

9:50–10:20 AM

FIRESIDE CHAT Has the Field of Cell Plasticity and Cancer Stem Cell Biology Come of Age as a Therapeutic Target?

Christine Chaffer, Founder and Chief Executive Officer, Kembi Therapeutics; Lab Head, Garvan Institute

Bob Weinberg, Professor for Cancer Research, Core Member, Whitehead Institute, MIT

Moderator: Janie Merkel, Corporate Strategy Officer for Health & Life Sciences, Yale Ventures

10:20–11:05 AM

PANEL Cracking the Code on Drugging Oncology’s Toughest Targets and Transforming Patient Outcomes

Jan Smith, Chief Scientific Officer, Revolution Medicines

Angela Cacace, Chief Scientific Officer, Arvinas

Jonathan Hurov, Executive Vice President, Discovery Biology, Parabilis Medicines

Moderator: Danette Daniels, Vice President, Protein Degrader Platform, Foghorn Therapeutics

11:05–11:35 AM

BREAK

11:35 AM–12:00 PM

PANEL Policy and Access in Oncology: Overcoming Barriers to Treatment

Victoria Barghout, Chief Executive Officer and Founder, Viver Health LLC

Margaret Callahan, Chief, Division of Hematology and Oncology, The University of Connecticut School of Medicine

Jeff Gordon, Connecticut State Senator

Dawn Holcombe, Executive Director, Connecticut Oncology Association

Premkumar Padmanabhan, President, Hartford Healthcare Medical Group

Moderator: Jodie Gillon, President & Chief Executive Officer, BioCT

12:00–12:20 PM

FIRESIDE CHAT From COVID Vaccines to Tumor Vaccines: Reflections and Opportunities for Breakthrough Innovation

Tal Zaks, Partner, OrbiMed Advisors LLC; Former Chief Medical Officer, Moderna

Steven Rosenberg, Chief Surgical Branch, NCI (Invited)

Moderator: TBD

12:20–12:55 PM

PANEL Immuno-Oncology, ADCs, Cell Therapies: The Big Picture and Emerging Modalities

Mika Derynck, Senior Vice President, Therapeutic Area Head of Oncology, Gilead

Jay Fine, President of R&D, EvolveImmune

Andy Souers, Vice President & Distinguished Research Fellow, Oncology Discovery Research, AbbVie

Moderator: TBD

12:55–1:55 PM

Lunch and Networking

1:55–2:30 PM

MINI-KEYNOTE Data Science and Tools in MedTech Innovation

Peter Schulam, Chief Scientific Officer, Johnson & Johnson MedTech

2:30–3:05 PM

PANEL Platform Technologies and Therapeutics Innovation

Iya Khalil, Vice President & Head of Data, AI & Genome Sciences, Merck

Matthew Hewitt, Vice President, CTO Manufacturing and Operations, Charles River Laboratories

Robert Abel, Executive Vice President, Chief Scientific Officer, Platform, Schrödinger

Molly He, Chief Executive Office, Element Biosciences

Moderator: David Weinstock, Venture Partner, RA Capital, Former Senior Vice President and Global Head of Oncology, Pharma R&D, Roche; Former Vice President of Discovery Oncology, Merck

3:05–3:40 PM

PANEL Investing for Innovation in Oncology

Gwen Cheni, Director of AI/Q Fund, Connecticut Innovations

Avi Kometz, Partner, Medical Technologies, Deerfield

Maha Radhakrishnan, Sofinnova Ventures

David Reshef, Venture Partner, Life Sciences, Google Ventures

Steve Squinto, Chief Investment Officer, JP Morgan Life Science Partners

Moderator: David Scheer, President, Scheer & Company

3:40–4:05 PM

PANEL Corporate Collaborations, Strategic Partnerships, and M&A as Drivers of Innovation

Scott DeWire, Corporate Senior Vice President, Global Head of BD&L, Boehringer Ingelheim

Michael Diem, Senior Managing Partner, Pfizer Ventures, Vice President, WW Business Development, Pfizer